{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.2","value":"2960"}]}],"title":"Abemaciclib"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"70.2","value":"1640"}]}],"title":"M2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"69.6","value":"2870"}]}],"title":"M20"}],"denoms":[{"counts":[{"groupId":"OG000","value":"326"}],"units":"Participants"}],"description":"Area Under the Plasma Concentration versus Time Curve from Time Zero to Infinity (AUC\\[0-∞\\]) was evaluated for Abemaciclib and Metabolites M2 and M20.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Abemaciclib 150 mg administered orally every 12 hours on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500mg administered IM on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation were met.","id":"OG000","title":"Abemaciclib + Fulvestrant"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All randomized participants who received at least one dose of 150 mg study drug (Abemaciclib) with evaluable Abemaciclib, M2 and M20 PK data.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 2-4 hours (h) post dose, Cycle 1 Day 15 4 and 7h post dose, Cycle 2 Day 1 pre dose and 3h post dose, Cycle 3 Day1 pre dose","title":"Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) of Abemaciclib, Its Metabolites M2 and M20","type":"SECONDARY","unitOfMeasure":"Nanograms*hour/milliliters (ng*h/mL)"}